New cancer Drug's interaction with other meds under scrutiny in early trial
NCT ID NCT07372625
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study is looking at how a new drug called rezatapopt affects the way the body processes four common medications (metformin, rosuvastatin, repaglinide, and midazolam) in people with advanced solid tumors that have a specific genetic mutation (TP53 Y220C). The goal is to see if rezatapopt changes the levels of these other drugs in the blood. Only 14 participants will be enrolled, and the study is primarily about safety and drug interactions, not about curing the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rezatapopt
What this could lead to
If successful, this study could help doctors understand how rezatapopt interacts with common medications, guiding safer use in future treatments.
What could go wrong
This is a very early, small phase 1 trial with only 14 participants. It focuses on drug interactions, not on treating the cancer itself, so it may not lead to direct patient benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Florida Cancer Specialists
RECRUITINGOrlando, Florida, 32827, United States
Contact Email: •••••@•••••
-
HealthOne Denver
RECRUITINGDenver, Colorado, 80237, United States
Contact Email: •••••@•••••
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Email: •••••@•••••
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
Contact Email: •••••@•••••
-
SCRI at Mary Crowley
RECRUITINGDallas, Texas, 75230, United States
Contact Email: •••••@•••••